GEN News Story - Difficulty in Patenting Improved Antibodies

In Centocor Ortho Biotech, Inc. v. Abbott Laboratories (Feb. 23, 2011), the U.S. Court of Appeals for the Federal Circuit (the Federal Circuit) recently revisited the written description requirement set forth in 35 U.S.C. § 112, first paragraph, and invalidated Centocor’s U.S. Patent No. 7,070,775 (the ‘775 patent), thus clarifying the standard as applied to antibody patent claims. Read more....   Difficulty in Patenting Improved Antibodies

As always, we encourage you to share your thoughts.

Best to all,

Debbie Robertson